How Recent Developments Are Shaping the OptimizeRx Investment Story [Yahoo! Finance]
OptimizeRx (NASDAQ:OPRX) had its "sell (d+)" rating reaffirmed by analysts at
Weiss Ratings.
OptimizeRx (NASDAQ:OPRX) was upgraded by analysts at Zacks Research from a "hold" rating to a "strong-buy" rating.
OptimizeRx (NASDAQ:OPRX) had its price target lowered by analysts at Stephens from $20.00 to $17.00. They now have an "equal weight" rating on the stock.
OptimizeRx (OPRX) Q3 2025 Earnings Call Transcript [Yahoo! Finance]